AstraZeneca says new results reinforce Tagrisso as backbone therapy
Easily identify stocks' risks and opportunities.
Discover stocks' market position with detailed competitor analyses.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
Disclaimer & DisclosureReport an Issue
AstraZeneca call volume above normal and directionally bullish
AstraZeneca announces results presented at ELCC on Tagrisso
Merck (NYSE:MRK) Becomes Latest Big Pharma Stock to Tap China with $2B Heart Disease Drug Rights Deal
China Woos Foreign CEOs with Call to Resist Protectionism as Trump Weighs Tariffs
AstraZeneca (AZN) Invests $2.5B in China R&D Hub
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration ('FDA') for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI). The HERNEXEOS, developed by Boehringer Ingelheim, is the first and only FDA-approved orally administered targeted therapy for adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). The recent approval is expected to bolster Thermo Fisher's Specialty Diagnostics arm. About TMO's Oncomine Dx Target Test The Oncomine Dx Target Test checks if NSCLC tumors harbor human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations. It enables multi-biomarker analysis from a single tissue sample to aid treatment decisions in as little as four days. This reduces the need for second biopsies and avoids suboptimal therapy selection in the absence of a complete biomarker report. The test is fully reimbursed by Medicare, as well as by the top 20 commercial payers in the United States. Oncomine Dx Target Test's Global Approvals The Oncomine Dx Target Test received its first approval by the FDA as an NGS CDx in 2017, followed by regulatory approvals in 20 countries for 11 biomarkers and over 20 targeted therapies. The test is reimbursed by government and commercial insurers in the United States, Europe, Japan, South Korea and Israel, covering more than 550 million lives globally. In the United States alone, it is approved for targeted therapies in NSCLC, cholangiocarcinoma (CC), astrocytoma (AC) and oligodendroglioma (OG), anaplastic thyroid cancer (ATC), medullary thyroid cancer (MTC) and thyroid cancer (TC). Industry Prospects Favor TMO According to the American Cancer Society, lung cancer is the second most common cancer in both men and women in the United States, with NSCLC accounting for about 85-90% of all lung cancer cases. Research further indicates that roughly 2-4% of NSCLC patients carry a HER2 mutation. With lung cancer cases continuing to rise, the global market for NSCLC treatments is expected to expand significantly, reaching $66.04 billion by 2032 at a CAGR of 10.3% from 2024 to 2032 (per Fortune Business Insights). Another Development by TMO Thermo Fisher recently announced the FDA approval for Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay for use as a companion diagnostic (CDx) for Dizal's ZEGFROVY (sunvozertinib) and in tumor profiling. Offerings by TMO's Competitors In the oncology space, Thermo Fisher faces competition from some prominent MedTech players. These companies are also making notable developments in their respective businesses. An expanding NGS oncology portfolio is helping Illumina ILMN drive the revolution in cancer genomics. The company's market-leading TruSight Oncology assay, TSO 500, continues to see increased utilization and broader adoption. In February, the company announced a new single-cell offering for CRISPR research with applications in oncology, immunology and drug target discovery. In 2024, the FDA approved its in vitro diagnostic (IVD) TSO Comprehensive test and its first two companion diagnostic (CDx) indications to rapidly match patients to targeted therapies. This year, Illumina is set to roll out TSO 500 v2, a new version that includes hundreds of genes across all variant classes and immuno-oncology biomarkers in a single assay from one sample, to facilitate therapy selection research. A rapidly expanding liquid biopsy and NGS-based testing portfolio is positioning Guardant Health GH as a leader in precision oncology. The company's flagship Guardant360 test has been recently enhanced with the Guardant Infinity platform, enabling a single blood draw to provide comprehensive tumor profiling, confirm the absence of actionable mutations and determine ER/PR/HER2 status. Regulatory milestones include approvals for Guardant360 CDx as a companion diagnostic in the United States, Japan and Singapore, covering multiple cancer targets such as EGFR and HER2 mutations. Its pipeline also includes the FDA-approved Shield blood test for colorectal cancer screening, offering a non-invasive alternative to colonoscopy. Exact Sciences' EXAS flagship screening product, the Cologuard test, is a non-invasive, stool-based DNA (sDNA) screening test that utilizes a multitarget approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company's precision oncology portfolio also offers the Oncotype DX Breast Recurrence Score test to identify patients who are most likely to benefit from chemotherapy, as well as those who may receive no clinical benefit from chemotherapy. Its Oncotype DX Colon Recurrence Score test is a multi-gene test for predicting recurrence risk in patients with stage II and stage III A/B colon cancer to enable an individualized approach to treatment planning. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report Guardant Health, Inc. (GH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Newsweek
17 hours ago
- Newsweek
No Time for the Doctor? You Can Give Yourself a Flu Vaccine
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. AstraZeneca's FluMist nasal spray, which was first approved by the U.S. Food and Drug Administration (FDA) in 2003, is now available through prescription for at-home use, a statement issued by the company said Friday. Newsweek has reached out to the American Medical Association (AMA) for comment on the vaccine on Saturday. Why It Matters While it's not a new vaccine, FluMist Home nasal spray widens the availability to those who may not previously had access. The at-home option also removes the need for a doctor to administer the vaccine, which public health experts say could increase vaccination uptake by addressing convenience and needle-avoidance barriers. This comes ahead of the 2025-26 influenza season in hopes to prevent the unusually high caseload seen the previous season. What To Know FluMist Home uses the same live attenuated intranasal formulation that is available in clinical settings like doctors' offices. The product is approved for children as young as 2 years old and up to adults aged 49. People who are pregnant, immunocompromised, and minors who take aspirin are advised not to take the vaccine, according to the company. Based on data from October 1, 2024, through May 17, 2025, the U.S. Centers for Disease Control and Prevention (CDC) estimated that there were up to 82 million flu related cases, 37 million medical visits, 1.3 million hospitalizations and 130,000 deaths across the U.S. during the 2024-25 flu season. The CDC says the best way to prevent the flu is to get a vaccine, however it's not available to everyone. Only 34 states, about 80 percent of the eligible population, have the option for the at-home vaccine, according to AstraZeneca's Friday statement. "There are a number of states where FluMist Home is unavailable due to local pharmacy laws," the statement said. "Our aim is to have this service available in all 48 contiguous states in future seasons." People over the age of 18 can go online, fill out a medical questionnaire and have the vaccine sent to them for self-administration. A sign telling customers that they can get a flu shot in a Walgreens store is seen on September 16, 2014, in Indianapolis. A sign telling customers that they can get a flu shot in a Walgreens store is seen on September 16, 2014, in Indianapolis. AP Photo/Darron Cummings, File What People Are Saying Joris Silon, US Country President and Senior Vice President, AstraZeneca, said in the statement issued Friday: "The launch of FluMist Home is a transformational moment in the evolution of influenza protection, bringing a simple and accessible option directly into the hands of consumers. FluMist Home reflects the growing importance of direct-to-consumer offerings and underscores our commitment to continuous innovation, making it easier for people to get vaccinated and stay protected." Dr. Peter Hotez, co-director of the Center for Vaccine Development at Texas Children's Hospital, told CNN Friday: "We learned during COVID how home diagnostic testing became widely accepted and that turned out to be a great public health intervention. Given the low uptake of seasonal flu vaccine in America, I think it is worth exploring some novel approaches." What Happens Next? It is unclear how many people will order the vaccine, but the outcomes of availability will be monitored by public health officials to see if the number of vaccinated patients, the number of cases, and even deaths change amid the newly available home vaccine. AstraZeneca urges users to report any side effects from taking the FluMist Home.
Yahoo
18 hours ago
- Yahoo
AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination
AstraZeneca recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important milestone for easier access to vaccinations in 34 U.S. states. This initiative likely contributed to its stock price increase of 12% last quarter, as it aligns with AstraZeneca's push towards innovative healthcare solutions. Despite this positive development, the overall market also experienced an upward trend, with the Dow hitting record highs and the market up 1% over the last week. AstraZeneca's performance seems to have been buoyed by both its strategic product launches and the broader market gains. Every company has risks, and we've spotted 2 possible red flags for AstraZeneca you should know about. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The launch of AstraZeneca's "FluMist Home" aligns well with the company's focus on innovative healthcare solutions, potentially impacting the narrative around its future growth. This new service might enhance revenue streams by tapping into the demand for convenient medical solutions. Over the last five years, AstraZeneca's total shareholder returns, including both share price and dividends, have risen by 54.08%. This growth provides a broader context to the company's performance, indicating resilience and strong returns for investors. Over the past year, AstraZeneca's share price movement has been in line with the performance of the UK Pharmaceuticals industry, which returned 10.3%. Looking at the potential impact on revenue and earnings forecasts, the initiative could bolster AstraZeneca's earnings as analysts anticipate a growth to $13.9 billion by 2028, up from $8.3 billion today. The recent stock price increase narrows the gap to the consensus analyst price target of £137.89, reflecting a potential 18.95% discount from the current share price of £115.92. This price movement suggests optimism among investors regarding the company's ability to meet future expectations. Our comprehensive valuation report raises the possibility that AstraZeneca is priced lower than what may be justified by its financials. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:AZN. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
